MADRIGAL PHARMACEUTICALS INC

NASDAQ: MDGL (Madrigal Pharmaceuticals, Inc.)

Last update: 6 days ago, 6:42PM

433.03

0.43 (0.10%)

Previous Close 432.60
Volume 296,514
Price / Earnings (Forward) 62.24
Price / Sales 6.99
Price / Book 16.02
52 Weeks Range
353.54 (-18%) — 615.00 (42%)
Profit Margin -123.38%
Operating Margin (TTM) -57.79%
Diluted EPS (TTM) -17.83
Total Debt/Equity (MRQ) 16.85%
Current Ratio (MRQ) 5.91
Operating Cash Flow (TTM) -395.31 M
Levered Free Cash Flow (TTM) -274.11 M
Return on Assets (TTM) -25.56%
Return on Equity (TTM) -50.16%

AIStockmoo Score

-0.2
Value 30% 0.0
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
Timing 30% -1.4
From our AI technical analysis of the chart. info NA
No clear trend over the past year. Far below its 52-week high. info
Recent bearish reversal pattern: Shooting star. info
Trend for Your Holding Period info NA
Sentiment 20% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money 20% 1.1
Insiders net buying recently. info
Institutional Flow info NA
Short Interest info NA
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Not in score
Price is low against its 52-week average. Up over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Price is between support and resistance. info
Final Score -0.20

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Madrigal Pharmaceuticals, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MDGL - - - 16.02
FOLD 5 B - - -
IGMS 71 M - - 0.760
SLGL - - - 3.80
ACAD - - - 2.34
COGT - - - 11.00

Select this tab to load the latest available analysis.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 7.73%
% Held by Institutions 108.28%

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BAKER BROS. ADVISORS LP 399.77 - 91,806 36,700,965
KELLEY SHANNON T - 399.63 -1,077 -430,402
Aggregate Net Quantity 90,729
Aggregate Net Value ($) 36,270,563
Aggregate Avg. Buy ($) 399.77
Aggregate Avg. Sell ($) 399.63
Name Holder Date Type Quantity Price Value ($)
KELLEY SHANNON T Officer 06 Nov 2026 Automatic sell (-) 1,077 399.63 430,402
BAKER BROS. ADVISORS LP Director 06 Nov 2026 Buy (+) 76,140 399.63 30,427,828
BAKER BROS. ADVISORS LP Director 04 Nov 2026 Buy (+) 15,666 400.43 6,273,136

Recent Signals candle patterns and EMA crosses

▼ Shooting star Last session · 11 Nov
Buyers pushed the price well up but could not hold it, and it closed near the low, after a rise. A bearish reversal signal.
▼ Death cross 10 sessions ago · 28 Oct
Long term · EMA 50/200
The 50-day EMA crossed below the 200-day, a widely watched sign that the long-term trend has turned down.

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria